Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › VRDN
RICE HALL JAMES & ASSOCIATES, LLC position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
RICE HALL JAMES & ASSOCIATES, LLC reported holding 1,235,840 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$25.4M, representing 1.35% of its reported portfolio and ranking #21 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed VRDN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RICE HALL JAMES & ASSOCIATES, LLC's VRDN position evolved
RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in VRDN in Q4 2024 at 53,375 shares (US$1.0M). The position peaked in Q4 2025 at 884,532 shares, worth US$27.5M. Across 8 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 7 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,235,840 shares valued at US$25.4M — an increase of 59,934 shares quarter over quarter.. Notable position changes include a 580% increase in Q1 2025 (shares rose 4% over the following quarter), a 42% increase in Q2 2025 (shares rose 54% over the following quarter), a 65% increase in Q3 2025 (shares rose 44% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 53.38K | $1.02M | New |
| Q1 2025 | 362.89K | $4.89M | Add |
| Q2 2025 | 515.62K | $7.21M | Add |
| Q3 2025 | 851.66K | $18.38M | Add |
| Q4 2025 | 884.53K | $27.53M | Add |
| Q1 2026 | 898.61K | $17.58M | Add |
| Q2 2026 | 1.18M | $21.60M | Add |
| Q3 2026 | 1.24M | $25.45M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Bellevue Group AG (US$123.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Paradigm Biocapital Advisors LP 12.41M sh · $227.08M · Q3 2026
- Kynam Capital Management, LP 6.15M sh · $126.59M · Q3 2026
- Bellevue Group AG 6.73M sh · $123.67M · Q2 2026
- RTW INVESTMENTS, LP 4.98M sh · $102.03M · Q3 2026
- Fairmount Funds Management LLC 5.09M sh · $93.52M · Q2 2026
- Deep Track Capital, LP 3.83M sh · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Venrock Adviser, LLC 3.26M sh · $59.85M · Q2 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M sh · $51.48M · Q3 2026
- BAKER BROS. ADVISORS LP 2.38M sh · $43.78M · Q2 2026
- Caligan Partners LP 2.19M sh · $40.30M · Q2 2026
More on RICE HALL JAMES & ASSOCIATES, LLC
FAQ
How long has RICE HALL JAMES & ASSOCIATES, LLC held VRDN?
RICE HALL JAMES & ASSOCIATES, LLC has disclosed VRDN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is RICE HALL JAMES & ASSOCIATES, LLC's current position in VRDN?
As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 1.24M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $25.45M, representing 1.35% of its reported portfolio and ranking #21.
Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling VRDN?
In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC increased its position in VRDN. The position peaked in Q4 2025 at 884.53K shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Bellevue Group AG, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.